Physician profile
Hinal Patel
NPI 1578153946
$2,131.47
in general payments reported to CMS, 2019-2025
23 companies · $667 in 2025
The $667 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.79 · 2022: $419 · 2023: $483 · 2024: $523 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $414.83 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Cvrx, INC. | $303.15 | 2022-2023 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $233.81 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Exact Sciences Corporation | $222.31 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $215.84 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Optinose US, INC. | $134.38 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.24 | 2021-2025 | Jardiance, Tradjenta |
| Ars Pharmaceuticals Operations, INC. | $74.90 | 2025 | Neffy |
| Abiomed | $72.52 | 2023 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.79 | 2024-2025 | Xifaxan, Trulance |
| Genentech USA, INC. | $49.20 | 2024-2025 | Xolair |
| Glaxosmithkline, LLC. | $44.11 | 2023-2024 | Nucala, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $37.97 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $20.00 | 2025 | Dupixent |
| Abbvie INC. | $17.63 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $16.57 | 2023 | Heplisav-B |
| Biocryst US Sales Co., LLC | $16.01 | 2023 | Orladeyo |
| Merck Sharp & Dohme LLC | $15.67 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Daiichi Sankyo INC. | $15.00 | 2022 | |
| Pfizer INC. | $14.84 | 2024 | |
| Sumitomo Pharma America, INC. | $14.11 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $13.33 | 2023 | |
| Amgen INC. | $13.26 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hinal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.